We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Cookie Policy

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Africanian
  • News
  • News 24/7
  • Politics
  • Business
  • Health
  • Sports
  • Travel
  • World
    • US
    • Russia
    • Europe
    • Asia
    • America
  • Events
No Result
View All Result
Africanian
  • News
  • News 24/7
  • Politics
  • Business
  • Health
  • Sports
  • Travel
  • World
    • US
    • Russia
    • Europe
    • Asia
    • America
  • Events
No Result
View All Result
Africanian
No Result
View All Result
Home World Russia

Russia registers new Covid-19 drug to keep complications caused by virus ‘under control’

Russian developers have registered a new drug that may help alleviate the harshest complications caused by Covid-19, including lung failure. It’s hoped the treatment can buy time before a vaccine is found.

africanian
June 8, 2020
in Russia
1 0
0
Russia registers new Covid-19 drug to keep complications caused by virus ‘under control’
Share on FacebookShare on TwitterShare via Whatsapp
Levilimab is the second medication to receive state approval through a fast-track mechanism, implemented to give doctors more options to tackle the virus, which has already infected more than 459,000 and killed 5,725 in Russia, according to official statistics.

“I think we’ll be able to keep Covid-19 complications under control and minimize the harshest problems it causes,” Dmitry Morozov, general director of Biocad, the biopharmaceutical company behind the drug, wrote on Facebook.

By reducing the Covid-19 mortality rate, Levilimab will allow Russia to “buy time” before the vaccine against the coronavirus is made, and “the vaccine is surely coming soon,” he added.The drug is aimed at curbing the so-called ‘cytokine storm,’ a common complication from Covid-19 when the sick person’s immune system overreacts to the virus and the excessive inflammation leads to fatal outcome.

“The mechanism [used in Levilimab] is known to researchers around the globe. But all the rest was done in Russia, by our company, from scratch. There’s an original patented molecule,” Morozov told RT.

Levilimab’s highlight is that it can be administered not only to patients already in a serious condition, but used as a prophylactic to “prevent the ‘cytokine storm’ from occurring and allowing the patient to avoid intensive care and lung ventilation,” he pointed out.

Related Post

Russia: Medvedev Warns the West On Providing Weapons to Ukraine

Russia: Medvedev Warns the West On Providing Weapons to Ukraine

February 28, 2023
South Africa: Hosts China and Russia For Joint Maritime Exercises

South Africa: Hosts China and Russia For Joint Maritime Exercises

February 21, 2023

Burkina Faso: France Recalls Ambassador from Burkina Faso

January 27, 2023

Grains to West Africa Secured as UN Agree Deal With Russia

November 19, 2022

The drug, which will go into the market under the brand ILSIRA, is administered hypodermically unlike its foreign counterparts, which get into the system through the intravenous route.

“One shot and you don’t go into the emergency room. There are two syringes in a package. Their injected simultaneously or with some interval. And in a week the person is discharged from hospital,” Morozov said.Levilimab has proven itself as effective as its foreign counterparts and increased the speed of recovery for patients, Ekaterina Trifonova, who heads the infectious ward at the Central Clinical Hospital in Moscow, where the drug underwent clinical testing, told RT. During the first two weeks of trials, out of 45 Covid-19 patients who got the drug, ten were discharged, including a 92-year-old-man, while the rest remained in satisfactory condition, she added.

Source: RT
Tags: Covid-19Covid-19 drugRussia
africanian

africanian

Related Posts

Russia: Medvedev Warns the West On Providing Weapons to Ukraine
Europe

Russia: Medvedev Warns the West On Providing Weapons to Ukraine

by Africanian
February 28, 2023
South Africa: Hosts China and Russia For Joint Maritime Exercises
News

South Africa: Hosts China and Russia For Joint Maritime Exercises

by Africanian
February 21, 2023
Burkina Faso: France Recalls Ambassador from Burkina Faso
News

Burkina Faso: France Recalls Ambassador from Burkina Faso

by Africanian
January 27, 2023
No Result
View All Result

Africanian News

Is a dedicated project aimed at amplifying the voices of the African Ecosystem and Diaspora. We actively collaborate with initiatives to improve access to education and digital inclusion, both in traditional schools and through digital platforms, for African children.

It’s crucial to emphasize that none of the articles or images featured on our platform are intended for copyright infringement, neither now nor in the future. If you believe that any information, text, image, etc., may be subject to copyright and should be removed, please notify us by sending an email to info@africanian.com

Your dreams matter; your stories matter.

Feel free to explore collaboration opportunities with us. Share your articles, thoughts, interviews, experiments, or no-comment videos by reaching out to info@africanian.com. You can also subscribe to our mailing list to receive the latest updates from Africanian News.

News letter

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Log In

Sign In

Forgot password?

Don't have an account? Register

Forgot password?

Enter your account data and we will send you a link to reset your password.

Back to Login

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Accept

Add to Collection

  • Public collection title

  • Private collection title

No Collections

Here you'll find all collections you've created before.

No Result
View All Result
  • News
  • Politics
  • Business
  • Health
  • Sports
  • Entertainment
  • Tech
  • Travel
  • World

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.